Open AccessImportance of hyperphosphataemia in the cardio-renal axis
Author(s) -
William G. Goodman
Publication year - 2004
Publication title -
nephrology, dialysis, transplantation/nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfh1001
Subject(s) - medicine , renal osteodystrophy , secondary hyperparathyroidism , kidney disease , dialysis , hyperparathyroidism , intensive care medicine , hyperphosphatemia , hemodialysis , complication , disease , parathyroid hormone , calcium
Hyperphosphataemia occurs in nearly all patients with end-stage renal disease (ESRD). In the past, the need to manage hyperphosphataemia focused primarily on its role as a contributor to secondary hyperparathyroidism and renal osteodystrophy. There is now widespread recognition that disturbances in phosphorus metabolism and/or the therapeutic measures used to manage it are important risk factors for cardiovascular calcification. This serious complication of chronic kidney disease may contribute to the very high mortality rate from cardiovascular causes in patients undergoing long-term dialysis. New strategies for controlling serum phosphorus levels and for better management of mineral metabolism in general are required to address these issues in patients with ESRD.